These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
8. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065 [TBL] [Abstract][Full Text] [Related]
9. A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. Biswas A; Adhikari N; Bakhshi S; Gopinathan VR; Sharma MC Pediatr Neurosurg; 2019; 54(1):57-65. PubMed ID: 30669145 [TBL] [Abstract][Full Text] [Related]
10. Multidrug chemotherapy, whole-brain radiation and cytarabine therapy for primary central nervous system lymphoma in elderly patients with dose modification based on geriatric assessment: study protocol for a phase II, multicentre, non-randomised study. Yamasaki F; Fudaba H; Asano K; Sasayama T; Natsumeda M; Shimabukuro T; Taguchi K; Koizumi S; Nakayama N; Fujii K; Nishibuchi I; Sugiyama K; Yoshida K; Yonezawa U; Yasutomo M; Kawasaki Y; Kakuta K; Katayama K; Tanaka K; Nagashima H; Tsukamoto Y; Ideguchi M; Nishizaki T; Kurozumi K; Hosoya T; Akita T; Kambe A BMJ Open; 2023 Apr; 13(4):e071350. PubMed ID: 37094899 [TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials. Yu J; Du H; Ye X; Zhang L; Xiao H Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528 [TBL] [Abstract][Full Text] [Related]
12. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma. Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782 [TBL] [Abstract][Full Text] [Related]
13. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma. Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120 [TBL] [Abstract][Full Text] [Related]
14. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma. Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986 [TBL] [Abstract][Full Text] [Related]
15. A nonradiation-containing, intermediate-dose methotrexate regimen for elderly patients with primary central nervous system lymphoma. Taoka K; Okoshi Y; Sakamoto N; Takano S; Matsumura A; Hasegawa Y; Chiba S Int J Hematol; 2010 Nov; 92(4):617-23. PubMed ID: 20967518 [TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235 [TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
19. Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. Kim YR; Kim SH; Chang JH; Suh CO; Kim SJ; Kim Y; Hwang DY; Jang JE; Hyun SY; Cheong JW; Min YH; Kim JS Ann Hematol; 2014 Feb; 93(2):211-9. PubMed ID: 23903866 [TBL] [Abstract][Full Text] [Related]
20. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]